Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy

Liu, Chen MD*; Liu, Teli PhD*; Zhang, Jingjing PhD; Baum, Richard P. PhD; Yang, Zhi PhD*

doi: 10.1097/RLU.0000000000002780
Interesting Images

Prostate cancer with neuroendocrine differentiation is associated with a poor prognosis, rapid disease progression, and treatment resistance, and constitutes a diagnostic and therapeutic dilemma. We present images of 177Lu-DOTATATE scan and 68Ga-DOTATATE PET/CT scan conducted on a 65-year-old man with prostate cancer with neuroendocrine differentiation, whose disease progressed despite conventional treatment and 177Lu-PSMA radioligand therapy; however, an extraordinary radiographic tumor remission, biochemical response, and improvement of clinical symptoms were observed after the patient underwent 177Lu-DOTATATE peptide receptor radionuclide therapy.

From the *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing, China

Theranostics Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, Germany.

Received for publication March 7, 2019; revision accepted July 18, 2019.

C.L. and T.L. contributed equally to this work.

Conflicts of interest and sources of funding: Chen Liu was supported by grants from Interdisciplinary Medicine Seed Fund of Peking University (BMU2017MX007). None declared to the other authors.

Correspondence to: Zhi Yang, PhD, Department of Nuclear Medicine, Beijing Cancer Hospital, No. 52 Fucheng Rd, Beijing, 100142, China. E-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.